251 related articles for article (PubMed ID: 15291930)
21. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.
Wilensky J; Fiscella RG; Carlson AM; Morris LS; Walt J
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S28-33. PubMed ID: 16389058
[TBL] [Abstract][Full Text] [Related]
22. Glaucoma prescribing trends in England 2000 to 2012.
Connor AJ; Fraser SG
Eye (Lond); 2014 Jul; 28(7):863-9. PubMed ID: 24858531
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy as initial treatment in glaucoma and suspected glaucoma.
Mikelberg FS; Etminan M
Can J Ophthalmol; 2012 Jun; 47(3):240-2. PubMed ID: 22687299
[TBL] [Abstract][Full Text] [Related]
24. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.
van der Valk R; Webers CA; Schouten JS; Zeegers MP; Hendrikse F; Prins MH
Ophthalmology; 2005 Jul; 112(7):1177-85. PubMed ID: 15921747
[TBL] [Abstract][Full Text] [Related]
25. Prescribing Trends of Topical Glaucoma Medications in Australia From 2001 to 2017.
Perera N; Pinnuck BC; Jamieson MPH; Ling D; Williams M; Chen O
J Glaucoma; 2020 Mar; 29(3):175-183. PubMed ID: 31790066
[TBL] [Abstract][Full Text] [Related]
26. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
27. Medical costs of glaucoma and ocular hypertension in Italian referral centres: a prospective study.
Koleva D; Motterlini N; Schiavone M; Garattini L;
Ophthalmologica; 2007; 221(5):340-7. PubMed ID: 17728557
[TBL] [Abstract][Full Text] [Related]
28. [Mechanisms, clinical profile and role of prostaglandin and prostamide analogues in antiglaucomatous therapy].
Yu A; Welge-Lüßen U
Klin Monbl Augenheilkd; 2013 Feb; 230(2):127-32. PubMed ID: 23335086
[TBL] [Abstract][Full Text] [Related]
29. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
[TBL] [Abstract][Full Text] [Related]
30. Improving cost-effectiveness of hypertension management at a community health centre.
Edwards PR; Lunt DW; Fehrsen GS; Lombard CJ; Steyn K
S Afr Med J; 1998 May; 88(5):549-54. PubMed ID: 9638122
[TBL] [Abstract][Full Text] [Related]
31. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
32. Efficiency of glaucoma drug regulation in 5 European countries: a 1995-2006 longitudinal prescription analysis.
De Natale R; Le Pen C; Berdeaux G
J Glaucoma; 2011; 20(4):234-9. PubMed ID: 21682002
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
[TBL] [Abstract][Full Text] [Related]
34. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
35. Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization.
Trese MGJ; Lewis AW; Blachley TS; Stein JD; Moroi SE
J Ocul Pharmacol Ther; 2017 Oct; 33(8):591-597. PubMed ID: 28854348
[TBL] [Abstract][Full Text] [Related]
36. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
Flowers B; Wand M; Piltz-Seymour J; Berke SJ; Day D; Teague J; Smoot TM; Landry TA; Bergamini MV; Mallick S;
Clin Ther; 2006 Nov; 28(11):1803-11. PubMed ID: 17213000
[TBL] [Abstract][Full Text] [Related]
37. The use of ocular hypotensive drugs for glaucoma treatment: changing trend in Taiwan from 1997 to 2007.
Lin JC
J Glaucoma; 2015; 24(5):364-71. PubMed ID: 26039384
[TBL] [Abstract][Full Text] [Related]
38. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
[TBL] [Abstract][Full Text] [Related]
39. Chart documentation by general physicians of the glaucoma medications taken by their patients.
Jampel HD; Parekh P; Johnson E; Miller R
Am J Ophthalmol; 2005 Aug; 140(2):344-5. PubMed ID: 16086971
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA
Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
